BCP

The Promising Drug for Schizophrenia

BCP is a botanical compound, orally available, not driven from cannabis. It reverses both the positive and negative symptoms that are associated with Schizophrenia. We believe that BCP will become the new class of treatment for Schizophrenia based on a novel therapy to the CB2 receptor with selective agonist activity. Successful pre-clinical studies in mice models for Schizophrenia encourage us to continue and explore this further. BCP has a Low toxicity level of LD50 <5000 mg/kg and is safe to use in humans. BCP is already FDA approved for human use, effective as pain reliever, anti-inflammatory and anxiolytic. Successful Phase I safety study in humans.